Study of MYC Gene Changes and Immune Environment in Diffuse Large B Cell and High-Grade B Cell Lymphomas

What this Trial Is About

Researchers are investigating the relationship between MYC gene changes, lymphoma genetic mutations, and the immune environment in adults with Diffuse Large B-cell Lymphoma DLBCL or High-Grade B-cell Lymphoma HGBCL. These lymphomas are diverse diseases making up over a third of adult lymphomas, with survival rates of around 60-70% over five years. The study aims to better understand these genetic factors and their impact on disease outcomes to improve treatment approaches. This observational study includes patients diagnosed with DLBCL or HGBCL who have MYC gene rearrangements or increased MYC gene copies. Participants have received standard first-line chemotherapy treatments such as R-CHOP or intensified regimens. The study collects data retrospectively and prospectively to explore genetic markers, immune cell patterns, and clinical outcomes related to these MYC changes and other genetic alterations. Participants provide tissue samples and clinical information, which researchers analyze for genetic and histological features. The study evaluates how these factors relate to patient responses and survival over up to 36 months. Researchers also review treatment types, risk of disease recurrence, and the effectiveness of preventive therapies. The study spans from diagnosis after January 2019 through long-term follow-up, helping to identify potential prognostic and predictive markers in lymphoma.

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma